JonesTrading analyst Justin Walsh has maintained their bullish stance on ANRO stock, giving a Buy rating on August 18.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Justin Walsh has given his Buy rating due to a combination of factors surrounding Alto Neuroscience, Inc.’s promising pipeline and the broader depression treatment landscape. The company is advancing several key drugs, including ALTO-300, ALTO-207, and ALTO-101, with significant clinical milestones expected in the next 18 months. These developments are anticipated to address unmet needs in the treatment of depression, a field where current options are often insufficient.
Additionally, the increasing market acceptance of innovative treatments, such as esketamine for treatment-resistant depression, highlights the potential for Alto’s novel approaches. The involvement of experts like Dr. Sanjay Mathew, who specializes in psychopharmacology and experimental therapies, further underscores the credibility and potential impact of Alto’s research efforts. These elements collectively contribute to the optimistic outlook and Buy rating for ANRO stock.
According to TipRanks, Walsh is an analyst with an average return of -0.8% and a 32.82% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Bioline RX Ltd Sponsored ADR, and Beyond Air.
In another report released on August 18, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.